Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS301 in Advanced Solid Tumors With NTRK/ROS1/ALK Alterations
CTR20221078Phase 2Terminated
- Sponsor
- Hanhui Pharmaceutical
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-301 in Nonhematologic neoplasms, sponsored by Hanhui Pharmaceutical. Started May 2022; status: terminated.
02
Drugs
HS-301
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20221078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221078.